Novo Nordisk A/S has initiated a share repurchase program effective from November 11, 2024, intending to buy back up to DKK 20 billion worth of shares over the next 12 months, with DKK 3.1 billion allocated for the initial phase ending February 3, 2025. As of November 22, 2024, they have repurchased 21,035,086 B shares at an average price of DKK 830.77 per share, totaling DKK 17.5 billion in transaction value.